International Clinical Trial: A study evaluating the efficacy and safety of aumolertinib mesylate as first-line therapy in patients with EGFR-mutated stage IIIB-IV non-squamous non-small cell lung cancer (NSCLC) complicated by chronic obstructive pulmonary disease (COPD)

Geneva, Feb. 2 -- International Clinical Trials Registry received information related to the study (ChiCTR2600117077) titled 'A study evaluating the efficacy and safety of aumolertinib mesylate as first-line therapy in patients with EGFR-mutated stage IIIB-IV non-squamous non-small cell lung cancer (NSCLC) complicated by chronic obstructive pulmonary disease (COPD)' on Jan. 19.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Tianjin Chest Hospital

Condition: EGFR-mutated stage IIIB-IV non-squamous NSCLC complicated by COPD

Recruitment Status: Not Recruiting

Phase: N/A

Date of First Enrollment: 2026-01-20

Target Sample Size: Aumolertinib Mesylate First-Line Treatment Group:51;

Countries of Recruitm...